Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Ann Oncol 2014; 5:107–116 (doi: 10.1093/annonc/mdt523)

In the original manuscript, in Figure 2C, an extra line was inserted at the top of the forest plot, resulting in all of the lines being shifted downward and therefore not aligning with the correct numbers on the right side of the plot.

Figure 2C.

OS Forest plot for patients with WT KRAS tumors.

The corrected figure is below.

The authors apologize for the error.